Biotech stories
Eligible research organisations can now access OpenAI's updated GPT-Rosalind model, as the company widens its life sciences rollout worldwide.
The platform targets manual drug-development bottlenecks, from trial documents to safety case intake, as biopharma seeks faster compliant workflows.
The new specialisation should help healthcare and life sciences firms use governed AI and data tools to speed trials, discovery and patient insights.
AI in life sciences is boosting workflows rather than replacing scientists, as firms navigate regulation, data risks and uneven adoption across markets.
Life sciences firms could avoid costly FDA review delays as the software flags conflicting claims across filings before submissions are sent.
Research teams could see faster target discovery as OpenAI opens GPT-Rosalind to qualified US customers for biology and drug discovery work.
The Danish quantum software firm is pushing into life sciences now, adding senior hires and partners to sell hybrid tools before the market matures.
A handful of US artificial intelligence megadeals pushed global venture capital investment to USD $330.9 billion in the first quarter, KPMG said.
Pharmaceutical field teams could cut hours of searching to seconds as ACTO's new system routes approved information through compliance checks.
Iran-linked wiper cyber attack cripples Stryker plants, disrupting implant production and locking thousands of staff out of global networks.
The funding will help London-based Apoha commercialise a liquid data layer already used by Boehringer Ingelheim and other pharma groups.
The grants are set to speed the rollout of AI tools across healthcare, manufacturing and finance, helping GTA firms reach market sooner.
Healthtech startups are finding it harder to scale as weaker exits and tighter liquidity help drive Canadian VC investment down to CAD $1 billion in 2025.
The AUD $490 million Waterloo precinct is set to ease Sydney’s lab space shortage as it moves into delivery with major global partners.
The funding could help turn hospital infusions into self-injectable treatments, as the London-founded firm scales microgravity drug crystallisation.
Canada’s health tech sector is struggling to turn strong research into commercial scale, as panellists split over whether policy or private capital should lead.
The move gives UK life sciences firms a new source of scale-up capital as a funding gap has left many promising businesses short of backing.
The London biotech startup will use new funding to broaden deployments at major drugmakers, including Pfizer, and speed research decisions.
The funding will help expand Vancouver research, manufacturing and clinical trials, with hundreds of jobs and student co-op places expected to follow.
The extra cash will help the deeptech fund back more science-led start-ups outside London at larger pre-seed and seed rounds.
